ENVOYA

Gene therapy products; gene therapy products, namely polymer-based nanoparticles; nucleic acid-containing products, namely RNA and DNA; gene therapy products for the treatment of cancer, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, or inflammatory diseases or disorders; nanoparticle products for medical or veterinary purposes; microparticle products for medical or veterinary purposes; nanoparticles for medical or veterinary purposes; microparticles for medical or veterinary purposes; nanoparticles to encapsulate a payload for medical or veterinary purposes; microparticles to encapsulate a payload for medical or veterinary purposes; nanoparticles designed to encapsulate nucleic acids, proteins, small molecules for medical or veterinary purposes; microparticles designed to encapsulate nucleic acids, proteins, small molecules for medical or veterinary purposes; nanoparticles to encapsulate nucleic acids for medical or veterinary purposes; nanoparticles encapsulating payloads for medical or veterinary purposes; microparticles encapsulating payloads for medical or veterinary purposes; reagents for clinical or medical laboratory use

Pharmaceutical research and development; research and development services; gene therapy research and development services; research and development collaboration services to enhance the delivery of RNA and DNA therapeutics to patients; research and development collaboration services in the field of pharmaceuticals; research and development collaboration services in the field of nanoparticles and microparticles; research and development collaboration services in the field of nucleic acid-containing particles; research and development collaboration services in the field of nucleic acids, proteins, and small molecules delivery; encapsulating nucleic acids, namely RNA and DNA, in tailored nanoparticles for targeted delivery; analyzing nanoparticle characteristics; analyzing microparticle characteristics; research and development collaboration services in the field of pharmaceutical preparations for the treatment of disease or disorders; research and development collaboration services in the field of pharmaceutical preparations for the treatment of cancer, muscular dystrophy, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, inflammatory diseases or disorders, rare diseases; scientific and technological services in the field of nucleic acids, proteins, and small molecules delivery to human cells; scientific and technological services in the field of protein delivery to human cells; research and design relating to scientific and technological services in the field of nucleic acids, proteins, and small molecules therapeutics